1978 W Winton Ave
Be part of pandemic-speed manufacturing for medicines
Talent is, and will always be, at the heart of our business. As part of our long-term growth strategy, we plan for significant expansion in Hayward, CA over the next 3 years. We are looking for talent to join us in various positions such as Quality Assurance, Operations, Regulatory, Engineering, Program Management, and many more.
We are one of the world's leading and most trusted suppliers to the pharmaceutical and biotech markets. We continue to break new ground within our industry, attracting global clients to our Hayward site. Rooted in the Bay Area and close to innovation in vaccines and therapeutics, we provide state-of-the-art, single-use manufacturing technology to support our customers with their clinical programs and through to commercial launch. Whether our customers are developing life-saving therapies for cancer or potential treatments for COVID-19, we can support them with world class manufacturing and process excellence.
With a history that dates back to 1897, Lonza is a trusted name with a wealth of knowledge and expertise in life science. Today we are more than 15,000 employees in more than 100 locations around the world. Together in 2019, we supported the development and production of over 1000 therapies.
We offer you exposure to upcoming biotech and established pharmaceutical companies and to the manufacturing technology needed to produce the potential blockbuster treatments of tomorrow. While other companies may only offer you the opportunity to work on a few treatments, at Lonza you will be working on scores of treatments per year for a variety of customers.
We are here to make a meaningful difference. It is the foundation of the way we do business. Looking after our people, our customers, our planet is core to our purpose. A career at Lonza is more than a job. We do not just work in the life sciences industries, we are transforming it. What we do today is helping to create a healthier, happier world tomorrow. That’s the meaningful difference we make every day.
211 articles with Lonza
Lonza announced that Marc Funk, CEO, will leave the Company for personal reasons. The Board of Directors also announced that Albert Baehny, Chairman, will take on the additional responsibility of Chief Executive Officer on an ad interim basis until a permanent successor is found.
Lonza Partners with Cryoport and Strengthens its 'Vein-to-vein' Delivery Network in Cell & Gene Therapy
Cryoport as a preferred partner for Lonza in the transport and delivery of patient tissues on a global basis
Lonza to Host New Webinar – “Paper to EBR in 9 Months: How a Strong Collaboration Leads to Project Success”
Free Lonza webinar to discuss the benefits of a collaborative approach to implementing an Electronic Batch Record Platform
Mesoblast and Lonza Enter Into Agreement for Commercial Manufacture of Mesoblast’s Potential First United States Allogeneic Cell Therapy
Mesoblast and Lonza announced that they have entered into an agreement for commercial manufacture of Mesoblast’s lead allogeneic cell therapy product candidate, remestemcel-L for pediatric steroid-refractory acute graft versus host disease
Lonza’s Ibex™ Design planned to take Genmab’s pre-clinical candidates from gene to potential IND within 12 months
The two companies will partner on the process development, analytical development and large-scale manufacturing for late-stage clinical and commercial supply.
Lonza’s MODA-ES™ Platform helps Nephron Pharmaceuticals move from paper to an EBR in nine months – Case study to be presented at 2019 ISPE Annual Meeting
Lonza has partnered with Nephron Pharmaceuticals Corporation to implement Lonza’s next-generation MODA-ES™ EBR Platform to streamline manufacturing compliance reporting
Omeros and Lonza have successfully partnered under a multi-year manufacturing agreement for the clinical supply of narsoplimab.
Expansion to bioconjugation facility in Visp, Switzerland to meet increasing clinical, launch and commercial market demand
Double-digit sales growth delivered by Pharma Biotech & Nutrition (LPBN) segment
Financial details of the deal were not disclosed, but Lonza said it plans to retain the Novartis employees currently working at the facility.
Lonza reports restated 2018 financials for sales, CORE EBITDA and CORE EBIT
Carve-out of Lonza Specialty Ingredients will help segment to become a global leader in microbial control
Lonza Group announced its intention to proceed with a carve-out of its Specialty Ingredients segment.
All investments in healthcare businesses progressing as planned to further accelerate growth
Lonza announced the adjustment of its Mid-Term Guidance 2022 to reflect the divestment of its former Water Care business unit and to emphasize Lonza's focus on growth along the Healthcare Continuum®.
Lonza announced the completion of the divestment of its former Water Care business and operations to Platinum Equity for USD 630 million.
Lonza Strengthens Pharma, Biotech and Nutrition Offerings with Aligned Structure and New Executive Committee Appointment
Lonza announced the internal alignment of its business structure to accelerate growth along the Healthcare Continuum® and strengthen the Microbial Control business.
Lonza announced that Richard Ridinger, CEO, has decided to retire from the company after seven successful years.
Lonza Achieved Another Excellent Full-Year Result in 2018 with 9% Organic Sales Growth and Strong Profitability Driven by Healthcare Businesses
Lonza reported a 9% organic sales, 12% organic CORE EBITDA and 14% organic CORE EBIT growth.
Fridtjof Helemann will leave the company on 31 March 2019, upon reaching retirement age.